Paul Hastings Advised NervGen Pharma on Its Bought Deal Offering
March 29, 2024
March 29, 2024
LOS ANGELES, California, March 29 -- Paul Hastings, a law firm, issued the following news on March 28, 2024:
Paul Hastings LLP advised NervGen Pharma Corp. in connection with the company's bought deal offering.
NervGen Pharma Corp. (TSXV: NGEN) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease.
Partner and co-chair of Equity Cap . . .
Paul Hastings LLP advised NervGen Pharma Corp. in connection with the company's bought deal offering.
NervGen Pharma Corp. (TSXV: NGEN) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease.
Partner and co-chair of Equity Cap . . .